Our pipeline
We are passionate about science.
We have a diversified and balanced portfolio covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.
The company also has a vaccine platform discovering and developing glycoconjugate vaccines containing synthetic antigenic glycan molecules with and without a carrier protein to prevent infection.
|
Compound |
Mechanism of action |
Target indication |
Status |
More Information |
|
QUVIVIQ™ (daridorexant) |
Dual orexin receptor antagonist |
Insomnia |
Commercially available in the US, Germany, Italy, and Switzerland; |
|
|
Aprocitentan* |
Dual endothelin receptor antagonist |
Difficult-to-control (resistant) hypertension |
NDA under review in the US, MAA under review in the EU, other filings in preparation |
|
|
Lucerastat |
Glucosylceramide synthase inhibitor |
Fabry disease |
Phase 3 primary endpoint not met, Open Label Extension study (OLE) ongoing |
|
|
Selatogrel |
P2Y12 inhibitor |
Suspected acute myocardial infarction |
Phase 3 recruiting |
|
|
Cenerimod |
S1P1 receptor modulator |
Systemic lupus erythematosus |
Phase 3 recruiting |
Investor webcast |
|
ACT-1004-1239 |
ACKR3 / CXCR7 antagonist |
Multiple sclerosis and other demyelinating diseases |
Phase 2 in preparation |
|
|
Sinbaglustat |
GBA2/GCS inhibitor |
Rare lysosomal storage disorders |
Phase 1 complete |
|
|
ACT-1014-6470 |
C5aR1 antagonist |
Immune-mediated disorders |
Phase 1 |
|
|
ACT-777991 |
CXCR3 antagonist |
Recent-onset Type 1 diabetes |
Phase 1 |
|
|
IDOR-1117-2520 |
Undisclosed |
Immune-mediated disorders |
Phase 1 |
|
|
IDO-090 |
Synthetic glycan vaccine |
Clostridium difficile infection |
Phase 1 in preparation |
* In collaboration with Janssen Biotech.
Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 was investigated in a Phase 2 study for the treatment of a rare form of pediatric epilepsy. The study did not meet the primary endpoint. ACT-709478 was generally well tolerated. Neurocrine continues to analyze the data generated in the study.
On July 20, 2023, Idorsia sold its operating businesses in the Asia Pacific (ex-China) region to Sosei Heptares, including the assignment of the license for PIVLAZ (clazosentan) for the Asia Pacific (ex-China) region. Idorsia retains the rights to clazosentan in the rest of the world.
Innovation fact sheet
For investors, we provide more information on how Idorsia is innovating to change treatment paradigms in our innovation fact sheet. Please visit the investor section for more information.